 |
|
UCF team's advanced nerve cell system could help cure diabetic neuropathy, related diseases
June 23, 2009Multiple sclerosis, diabetic neuropathy, and other conditions caused by a loss of myelin insulation around nerves can be debilitating and even deadly, but adequate treatments do not yet exist. That's in large part because of deficiencies in model research systems. In an upcoming issue of the journal Biomaterials, a UCF team addresses this problem with a report on the first lab-grown motor nerves that are insulated and organized the same way they are in the body. The group's model system, along with further advances now within reach, could dramatically improve understanding of the causes of myelin-related conditions, and enable discovery and testing of new drug therapies.
Nerve malfunctions, or neuropathies, involve a breakdown in the way the brain sends and receives electric signals along nerve cells. In mammals, these signals are able to travel long distances because of breaks in their myelin insulation called nodes of Ranvier, each of which chemically boosts the signal, allowing it to travel to the next node. "They're like power station relays," says James Hickman, a bioengineer at UCF who led the new research, which achieved the first successful nodes of Ranvier formation ever on motor nerves in a lab culture, among other advances.
Multiple sclerosis (MS), diabetic neuropathy, Guillain-Barré syndrome, and other demyelinating conditions are caused when nerve signals can't travel their normal path from node to node due to myelin breakdown. Within the brain and spinal cord, where the damage from MS occurs, cells called oligodendrocytes surround the nerves and produce this critical myelin. In the peripheral nervous system, where the problems associated with diabetic neuropathy originate, Schwann cells perform this function.
Due to the famous complexity of the nervous system, studying demyelinating neuropathies has proven exceedingly challenging. "People have basically been stuck doing work in animal models, and they don't work very well," says Hickman.
Researchers have long recognized the need for lab-grown motor nerve cells that myelinate and form nodes of Ranvier so that, under controlled laboratory conditions, they can zero in on the causes of and solutions for demyelination. Researchers have achieved Myelination and nodes of Ranvier formation with sensory neurons, but accomplishing the same task with the motor nerves that play more critical roles in some diseases has remained an elusive goal.
Working with Hickman, UCF graduate student John Rumsey was able to accomplish this very feat, though, for the first time. "It was exciting because it was totally unexpected," says Hickman. The key to their surprising successes is one that other researchers in the field may find surprising, and one that makes their new model system better suited to advancing neuropathy research than anything ever before available.
"It was such a long shot I didn't believe the results at first," says James Hickman, leader of the team that developed the new model, "It took two months before I was convinced we had what he had."
Accomplishing the Complex by Keeping It Simple
Nerve cells in the body grow in two strikingly different environments. In the relatively open peripheral nervous system, cells are exposed to blood and other fluids that contain high protein concentrations and copious other constituents in variable concentrations. In the isolated central nervous system the spinal cord and brain are instead surrounded by cerebrospinal fluid that is nearly sterile, with only a trace of protein.
Especially during initial experiments, researchers typically grow cell cultures in serum isolated from cow or human blood, which effectively promotes growth. But serum also complicates studies by making it difficult to discern the relative impacts of different chemical components. Once growth in serum is accomplished, researchers will often attempt culturing in a serum-free medium, especially for drug discovery work where serum's components make it difficult to isolate the effects of a drug.
Past research aimed at getting Schwann cells to myelinate motor nerves, or motoneurons, had followed this pattern, but the Hickman group began serum-free. They had already developed techniques for growing various nervous system cells in serum-free media, including motoneurons, so they decided to attempt myelination using the growth medium they have spent years tweaking.
Hickman hypothesizes that while serum contains components that promote cell growth it may also contain some that inhibit growth. Therefore, starting with a serum-free medium, rather than ending there, may well have led to the team's success.
What's Next: Drug Discovery Potential
Among numerous goals, the Hickman team plans to use their new model system to explore the origins of diabetic neuropathy, a condition that can cause a range of complications from digestive problems to pain in the limbs.
Currently researchers have incomplete understanding of even the basics of how demyelination occurs. So, one line of experiments will be to treat cultured motoneuron systems with factors found in high concentrations in diabetics, such as fatty acids or cholesterol. This will allow them to identify what causes myelin to degrade, which could in turn help them identify targets for new drug therapies that could also be tested using the model. Other planned experiments will focus on how electrical signals travel through myelinated and unmyelinated nerves to reveal how nerves malfunction.
"Being able to study these fully developed structures means we can really start looking at these things in a way that just wasn't possible before," says Hickman.
Though the myelination work has involved embryonic rat cells, the Hickman team was also the first to culture adult motoneurons and hopes to eventually extend myelination work to those as well. Such an advance would, for instance, offer a more realistic model for spinal cord injury research. Effective treatment of spinal injuries would be dependant on remyelination of adult motoneurons, including nodes of Ranvier formation. If that can be achieved in the lab, it will be a sign of hope that treatments could be developed to accomplish the same in patients.
Another major goal for the Hickman group will be to induce myelination by the oligodendrocytes that insulate the central nervous system motoneurons involved in multiple sclerosis, a goal preliminary experiments suggest may be achievable.
Even without that advance, the Schwann cell myelination model could reveal new drug treatment possibilities for multiple sclerosis based on improved understanding of demyelination. For the roughly 400,000 Americans and countless others around the globe suffering from this and other related diseases with limited treatment options, all these possibilities are sure to be welcome news.
University of Central Florida
Due to the famous complexity of the nervous system, studying demyelinating neuropathies has proven exceedingly challenging. "People have basically been stuck doing work in animal models, and they don't work very well," says Hickman.
Researchers have long recognized the need for lab-grown motor nerve cells that myelinate and form nodes of Ranvier so that, under controlled laboratory conditions, they can zero in on the causes of and solutions for demyelination. Researchers have achieved Myelination and nodes of Ranvier formation with sensory neurons, but accomplishing the same task with the motor nerves that play more critical roles in some diseases has remained an elusive goal.
Working with Hickman, UCF graduate student John Rumsey was able to accomplish this very feat, though, for the first time. "It was exciting because it was totally unexpected," says Hickman. The key to their surprising successes is one that other researchers in the field may find surprising, and one that makes their new model system better suited to advancing neuropathy research than anything ever before available.
"It was such a long shot I didn't believe the results at first," says James Hickman, leader of the team that developed the new model, "It took two months before I was convinced we had what he had."
Accomplishing the Complex by Keeping It Simple
Nerve cells in the body grow in two strikingly different environments. In the relatively open peripheral nervous system, cells are exposed to blood and other fluids that contain high protein concentrations and copious other constituents in variable concentrations. In the isolated central nervous system the spinal cord and brain are instead surrounded by cerebrospinal fluid that is nearly sterile, with only a trace of protein.
Especially during initial experiments, researchers typically grow cell cultures in serum isolated from cow or human blood, which effectively promotes growth. But serum also complicates studies by making it difficult to discern the relative impacts of different chemical components. Once growth in serum is accomplished, researchers will often attempt culturing in a serum-free medium, especially for drug discovery work where serum's components make it difficult to isolate the effects of a drug.
Past research aimed at getting Schwann cells to myelinate motor nerves, or motoneurons, had followed this pattern, but the Hickman group began serum-free. They had already developed techniques for growing various nervous system cells in serum-free media, including motoneurons, so they decided to attempt myelination using the growth medium they have spent years tweaking.
Hickman hypothesizes that while serum contains components that promote cell growth it may also contain some that inhibit growth. Therefore, starting with a serum-free medium, rather than ending there, may well have led to the team's success.
What's Next: Drug Discovery Potential
Among numerous goals, the Hickman team plans to use their new model system to explore the origins of diabetic neuropathy, a condition that can cause a range of complications from digestive problems to pain in the limbs.
Currently researchers have incomplete understanding of even the basics of how demyelination occurs. So, one line of experiments will be to treat cultured motoneuron systems with factors found in high concentrations in diabetics, such as fatty acids or cholesterol. This will allow them to identify what causes myelin to degrade, which could in turn help them identify targets for new drug therapies that could also be tested using the model. Other planned experiments will focus on how electrical signals travel through myelinated and unmyelinated nerves to reveal how nerves malfunction.
"Being able to study these fully developed structures means we can really start looking at these things in a way that just wasn't possible before," says Hickman.
Though the myelination work has involved embryonic rat cells, the Hickman team was also the first to culture adult motoneurons and hopes to eventually extend myelination work to those as well. Such an advance would, for instance, offer a more realistic model for spinal cord injury research. Effective treatment of spinal injuries would be dependant on remyelination of adult motoneurons, including nodes of Ranvier formation. If that can be achieved in the lab, it will be a sign of hope that treatments could be developed to accomplish the same in patients.
Another major goal for the Hickman group will be to induce myelination by the oligodendrocytes that insulate the central nervous system motoneurons involved in multiple sclerosis, a goal preliminary experiments suggest may be achievable.
Even without that advance, the Schwann cell myelination model could reveal new drug treatment possibilities for multiple sclerosis based on improved understanding of demyelination. For the roughly 400,000 Americans and countless others around the globe suffering from this and other related diseases with limited treatment options, all these possibilities are sure to be welcome news.
University of Central Florida
Neuropathy Current Events and Neuropathy News RSSMedical food reduces medical costs and use of anti-convulsant medication
Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food.
Chronic pain treatments work better together, says Queen's anesthesiologist
People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.
Scientists track impact of DNA damage in the developing brain
Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion.
Researchers design first model motor nerve system that's insulated and organized like the human body
In the July issue of Biomaterials, published by Elsevier, researchers from the University of Central Florida (UCF) report on the first lab-grown motor nerves that are insulated and organized just like they are in the human body.
Structural biology scores with protein snapshot
In a landmark technical achievement, investigators in the Vanderbilt Center for Structural Biology have used nuclear magnetic resonance (NMR) methods to determine the structure of the largest membrane-spanning protein to date.
DNA template could explain evolutionary shifts
Rearrangements of all sizes in genomes, genes and exons can result from a glitch in DNA copying that occurs when the process stalls at a critical point and then shifts to a different genetic template, duplicating and even triplicating genes or just shuffling or deleting part of the code within them, said researchers from Baylor College of Medicine in a recent report in the journal Nature Genetics.
New Jefferson study may redefine how a chronic auto-immune disease is diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed.
Marijuana rivals mainstream drugs for HIV/AIDS symptoms
Those in the United States living with HIV/AIDS are more likely to use marijuana than those in Kenya, South Africa or Puerto Rica to alleviate their symptoms.
Neurological disorder in golden retriever dogs caused by a mutation in mitochondrial DNA
Sensory ataxic neuropathy (SAN) is a recently identified neurological disorder in Golden Retriever dogs with onset during puppyhood.
A new mouse model provides insight into genetic neurological disorders
Neurosensory diseases are difficult to model in mice because their symptoms are complex and diverse. The genetic causes identified are often lethal when transferred to a mouse.
More Neuropathy Current Events and Neuropathy News Articles
 |
Peripheral Neuropathy: When the Numbness, Weakness, and Pain Won't Stop (American Academy of Neurology) by M.D. Norman Latov (Author) Peripheral neuropathy, the variety of conditions that result when the nerves that connect to the brain and spinal cord are damaged or diseased, is commonly associated with diseases such as diabetes, HIV, alcoholism, and lupus. Although widespread — it affects 10–20 million people in the United States — information about the condition has been difficult to obtain. This essential guide explains what is known about peripheral neuropathy, including its causes and manifestations, and what can be done to manage it. Topics include drug therapy for the condition and its symptoms, interventional therapy, alternative medicines, caring for the feet, and much more. This book will enable patients to make informed decisions about their care. |
 |
You Can Cope with Peripheral Neuropathy: 365 Tips for Living a Full Life by Mims Cushing (Author), M.D. Norman Latov (Author) Peripheral neuropathy has reached epidemic proportions in recent years. This condition has numerous causes, but can be associated with diseases such as HIV, alcoholism, diabetes, and lupus and may result from medical treatments such as chemotherapy. Symptoms include pain, numbness, loss of balance, and tingling or burning in the extremities. Although widespread, neuropathy is not well understood, and finding reliable information about it can be difficult. Written by a leading doctor in the field and a patient-expert, You Can Cope with Peripheral Neuropathy: 365 Tips for Living a Full Life covers such diverse topics as what to ask at doctor appointments, how to make the house easier to navigate, where to find a support group, how to use vitamins and herbs for treatment, ways to travel... |
 |
Nerve Support Formula Nutritional Supplement for Peripheral, Diabetic & Poly Neuropathy by Wellness Support Network It is important to understand that neuropathy is a condition that if you don't take effective action against, it simply gets worse. Unfortunately, drugs and medications only treat the symptoms and usally do nothing to addres the underlying causes. The good new is that cutting-edge science and nutrition have come together to create a truly monumental and nautral breakthrough for people who are affected by neuropathy. Up to 60% of all diabetics suffer from neuropathy, and there are many people with neuropathy from chemotherapy, toxins, trauma, etc. Neuropathy is a condition where the nerves around the periphery (outer part of the body) are damaged. This type of neuropathy can affect sensory nerves in the feet, legs, hands and arms, and it can occur on both sides of the body. It is one of... |
 |
Coping With Peripheral Neuropathy: How to handle stress, disability, anxiety, fatigue, depression, pain, and relationships by CIDP, Scott I Berman MD (Author) Peripheral neuropathies are a large group of chronic illnesses that cause changes in your life far beyond simply damaging nerves. Sufferers often confront pain, weakness, depression, anxiety, fatigue and insomnia. In addition there are long term changes in roles and relationships. Dr. Berman tackles these psychological and social issues in Coping with Peripheral Neuropathy from the viewpoint both of an experienced psychiatrist and of a fellow-sufferer with neuropathy. He details strategies to deal with changing roles at work and at home. He explores relationships and sexuality. Dr. Berman lays the groundwork for learning to cope and improve your quality of life in the face of these chronic diseases. He draws on experience treating chronically physically ill patients... |
 |
Nutrients for Neuropathy (Numb Toes) by John A. Senneff (Author) |
 |
NaturalCare NerveFix, Capsules, 60-Count Bottle by NaturalCare Naturally, and without drugs, NerveFix helps relieve the symptoms of numbness, tingling, burning, nerve pain, pins and needles and peripheral neuropathy, often a result of nerve irritation, localized swelling or injury. The hands, fingers, back, and even the face are the most commonly affected areas. |
 |
Numb Toes and Aching Soles: Coping with Peripheral Neuropathy by John A. Senneff (Author) A comprehensive guide for the millions who have painful and disabling peripheral neuropathy. Covered are causes, symptoms, tests and treatments- both conventional and alternative- and ways of coping day to day. The book is written from a patient's point of view with over 200 patient comments on treatments. There are also special sections for those with diabetic or HIV-related neuropathies (up to half in these groups are affected), as well as reports on experimental drugs in the pipeline. Inputs from 12 leading neurologists have been incorporated. |
 |
The Numb Foot Book - How to Treat and Prevent Peripheral Neuropathy (Numb Toes) by Dr. Alexander McLellan (Author), Dr. Marc Spitz (Author), April Jackson (Editor), Chris Gibson (Editor) The Numb Foot Book, is the latest addition to the best selling Numb Toes series, and has quickly become the must read book for Diabetics or anyone suffering from peripheral neuropathy. Drs. Alex McLellan and Marc Spitz have taken the reins from the legendary John Senneff, who pioneered layperson literature by focussing on treatment and coping options for neuropathy (nerve pain) sufferers. This new book is considered the best in the series to date. WHAT IS COVERED: 1-The latest information on medical treatment options, including oral and topical drugs and their side effects. 2-The most important nutritional supplements which can slow the progression or even reverse peripheral neuropathy. 3-New treatments such as Laser and Infrared... |
 |
Peripheral Neuropathy: 2-Volume Set by Peter James Dyck (Author), P. K. Thomas (Author) Edited by internationally acclaimed experts in the field, this authoritative 2-volume Gold Standard comprehensively covers the neurobiology and diseases of the peripheral nervous system. It encompasses neurobiology, clinical neurophysiology, molecular genetics, and clinical diagnosis and management. The 4th Edition has been rewritten and updated to provide a fresh account of all subjects, with an emphasis on new information about cell biology, genetics, proteomics, clinical manifestations, and new treatments. And, a user-friendly organization allows readers to quickly find specific information, or access more in-depth coverage when needed. * Provides authoritative, in-depth information on neurobiology and diseases of the peripheral nervous system. * Presents complete coverage of... |
 |
The Official Patient's Sourcebook on Peripheral Neuropathy: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to peripheral neuropathy (also Mononeuritis Multiplex; Mononeuritis, Peripheral; Mononeuropathym Peripheral; Multiple neuritis; Multiple Peripheral Neuritis; Neuritis - peripheral), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some... |
| © 2009 BrightSurf.com |